The effect comparison of lamivudine combined with adefovir and entecavir in treatment of chronic hepatitis B

Abstract

Objective To analyze the effect of lamivudine combined with adefovir and entecavir in treatment of chronic hepatitis B patients, to provide the basis for felicitous treatment. Methods 120 cases of chronic hepatitis B patients were divided into two groups(lamivudine combined with adefovir group and entecavir group) according to the method of treatment. The clinical data of two groups were recorded, including the cases of ALT normalization, HBeAg negative conversion and HBV DNA below to the detection level in different treatment time. Results After 3, 6, 12 months of treatment, there was no statistical difference between the two groups in ALT normalization ( x2 = 2.194,2.353,3.339, P＞ 0.05); and there was no statistical difference in the incidence of HBeAg negative after 3,6,12.18 months of treatment too(x2 = 0.054,0.139,0.326,0.152, P ＞ 0.05). There was no statistical difference in the incidence of HBV DNA returned to nagative after 6,12, 18,24 months trentment ( x2 = 0.348,0.348,2.236,0.776, P ＞ 0.05). Conclusions There was no difference in the ALT normalization, the incidence of HBeAg negative conversion and the incidence of HBV DNA retumed to nagative in lamivudine combined with adefovir and entecavir for chronic hepatitis B. Key words: Lamivudine; Adefovir; Entecavir; Therapeutic alliance; Hepatitis B